文献速递细菌感染、耐药与抗菌药物

加拿大医院革兰阴性病原菌17年监测结果

Gram-negative pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007-23).
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

OBJECTIVES: CANWARD is a Canadian Antimicrobial Resistance Alliance (CARA)/Health Canada partnered national surveillance study established in 2007 to annually assess the in vitro activities of commonly tested and recently approved antimicrobial agents for bacterial pathogens isol…

要点

  • 大肠埃希菌和肺炎克雷伯菌对美罗培南/伐博巴坦、亚胺培南/瑞来巴坦敏感率最高。
  • 铜绿假单胞菌对头孢他啶/阿维巴坦、头孢洛扎/他唑巴坦及亚胺培南/瑞来巴坦敏感率较高。
  • 大肠埃希菌和肺炎克雷伯菌中产ESBL表型分别占8.4%和5.6%。

核心结论

  • CANWARD监测研究提供了17年参考药敏试验数据。

研究设计与样本

  • CANWARD是加拿大抗菌药物耐药联盟与加拿大卫生部合作于2007年建立的全国监测研究。

主要发现

  • 分离株标本来源:呼吸道39.4%、血液37.1%、尿液17.7%、伤口5.8%。
  • 患者来源:内科病房31.1%、急诊23.9%、ICU 19.0%、医院门诊18.5%、外科病房7.5%。
  • 最常见病原菌:大肠埃希菌34.9%、铜绿假单胞菌17.5%、肺炎克雷伯菌11.6%。
  • 产ESBL表型:大肠埃希菌8.4%、肺炎克雷伯菌5.6%。

关键数值与推荐

  • 大肠埃希菌敏感率:美罗培南/伐博巴坦和亚胺培南/瑞来巴坦均为100%;头孢他啶/阿维巴坦、美罗培南和头孢洛扎/他唑巴坦均>99%;哌拉西林/他唑巴坦95.6%;环丙沙星73.9%。
  • 肺炎克雷伯菌敏感率:美罗培南/伐博巴坦、亚胺培南/瑞来巴坦、头孢他啶/阿维巴坦和美罗培南均>99%;头孢洛扎/他唑巴坦97.4%;哌拉西林/他唑巴坦91.9%;环丙沙星87.0%。
  • 铜绿假单胞菌敏感率:头孢洛扎/他唑巴坦96.6%;头孢他啶/阿维巴坦92.6%;亚胺培南/瑞来巴坦92.0%;哌拉西林/他唑巴坦79.9%;头孢他啶78.1%;美罗培南78.0%;环丙沙星68.6%。

临床怎么用

  • 可参考本监测数据了解加拿大医院革兰阴性菌对常用及新近批准抗菌药物的敏感情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: CANWARD is a Canadian Antimicrobial Resistance Alliance (CARA)/Health Canada partnered national surveillance study established in 2007 to annually assess the in vitro activities of commonly tested and recently approved antimicrobial agents for bacterial pathogens isolated from patients receiving care in Canadian hospitals. METHODS: In total, 34 155 Gram-negative pathogens were tested using the CLSI reference broth microdilution method. RESULTS: In total, 39.4%, 37.1%, 17.7% and 5.8% of isolates tested were from respiratory, blood, urine and wound specimens, respectively; 31.1%, 23.9%, 19.0%, 18.5% and 7.5% of isolates were from patients in medical wards, emergency rooms, ICUs, hospital clinics and surgical wards. In total, 51.8% of isolates were from male patients; and 10.1%, 40.7% and 49.2% of isolates were from patients aged ≤17, 18-64 and ≥65 years. The most common Gram-negative pathogens received were: Escherichia coli (34.9%), Pseudomonas aeruginosa (17.5%) and Klebsiella pneumoniae (11.6%). An ESBL-producing phenotype was identified in 8.4% of E. coli and 5.6% of K. pneumoniae isolates. Percent susceptible values for E. coli included: 100% for meropenem/vaborbactam and imipenem/relebactam; >99% for ceftazidime/avibactam, meropenem and ceftolozane/tazobactam; 95.6% for piperacillin/tazobactam; and 73.9% for ciprofloxacin. Percent susceptible values for K. pneumoniae included: >99% for meropenem/vaborbactam, imipenem/relebactam, ceftazidime/avibactam and meropenem; 97.4% for ceftolozane/tazobactam; 91.9% for piperacillin/tazobactam; and 87.0% for ciprofloxacin. Percent susceptible values for P. aeruginosa included: 96.6% for ceftolozane/tazobactam; 92.6% for ceftazidime/avibactam; 92.0% for imipenem/relebactam; 79.9% for piperacillin/tazobactam; ceftazidime 78.1%; 78.0% for meropenem; and 68.6% for ciprofloxacin. CONCLUSIONS: The CANWARD surveillance study has provided 17 years of reference antimicrobial susceptibility testing data.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Zhanel GG, Baxter MR, Lagacé-Wiens P, et al. Gram-negative pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007-23). J Antimicrob Chemother. 2025. PMID: 40873026. doi:10.1093/jac/dkaf217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。